ClinicalTrials.gg
RecruitingNCT07060456Updated Jan 2, 2026

Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin

A Phase 3 interventional study of HRS9531 and HRS9531 in Type 2 Diabetes, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-02.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing ribupatide in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, 1 of them phase 3. ribupatide · Diabetes Mellitus, Type 2.

Planned enrollment
2nd of 11
300 · median 72
Started
2025
the only one that year
Phase 3
3 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
11 of 11
Fujian Shengdi Pharmaceutical Co., Ltd.

Among the 11 studies testing ribupatide in Diabetes Mellitus, Type 2, this one is the 2nd largest by planned enrollment, is the only one that started in 2025, is one of 3 in phase 3, and was the 11th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 11 studies testing ribupatide in Diabetes Mellitus, Type 2 is open now, in 1 country.

By country, each count listing its studies:

Where they have run

About ribupatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing ribupatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The study is being conducted to evaluate the efficacy and safety of HRS9531 compared with placebo in participants with type 2 diabetes mellitus not adequately controlled with basal insulin, with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study may include up to 23 visits.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, able and willing to provide a written
  2. Diagnosed with type 2 diabetes ≥ 90 days;
  3. On stable once-daily dose of basal insulin alone or in combination with metformin and/or SGLT2 inhibitor ≥ 90 days;
  4. was 7.5%\~11.0% (both inclusive);
  5. (BMI) ≥22 kg/m2 at screening.

Exclusion criteria

Exclusion Criteria:

  1. A history of type 1 diabetes, specific diabetes, or secondary diabetes;
  2. Have a history of severe hypoglycemia within t180 days prior to screening;
  3. History of acute cardiovascular and cerebrovascular diseases within 180 days prior to screening;
  4. Have a history of within 5 years;
  5. Known or suspected allergy or intolerance to the medicinal products or related products;
  6. Participation in any clinical trial of an approved or non-approved investigational product/treatment within the last 90 days;
  7. Any conditions that the Investigator judges might not be suitable to participate in the trial.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Treatment group A: HRS9531-low dose

    Drug: HRS9531

  • Experimental
    Treatment group B: HRS9531-high dose

    Drug: HRS9531

  • Placebo comparator
    Treatment group C

    Drug: Placebo

Interventions

  • HRS9531-low dose

  • HRS9531-high dose

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change in HbA1c

    Change in HbA1c after 40 weeks of treatment.

    Time frame: from baseline to Week 40

Secondary outcomes

  1. Proportion of subjects reaching HbA1<7.0%

    Proportion of subjects reaching HbA1\<7.0% after 40 weeks of treatment.

    Time frame: from baseline to Week 40

  2. Proportion of subjects reaching HbA1≤6.5%

    Proportion of subjects reaching HbA1≤6.5% after 40 weeks of treatment.

    Time frame: from baseline to Week 40

  3. Change in FPG

    Change in FPG after 40 weeks of treatment.

    Time frame: from baseline to Week 40

  4. Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) Score

    Change from baseline in DTSQs after 40 weeks of treatment.

    Time frame: From baseline to Week 40

07

Study locations

1 of 1 sites recruiting
  • Perking University Peoples' Hospital
    Beijing, Beijing Municipality 100044, China
    Recruiting
    • Linong JI · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Feb 2027, 19 months after the start.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's planned 19 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2025
First posted
Jul 11, 2025
StartActual
Jul 25, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Mar 2027
Last update
Jan 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07060456
Responsible party
Sponsor
First posted
Jul 11, 2025
Start date
Jul 25, 2025
Primary completion
Feb 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Jan 2, 2026

Study contacts

Hong Chen
Contact
hong.chen@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion